Adicet Bio, Inc. (ACET) Insider Trading Activity

NASDAQ$3.025-0.02 (-0.66%)
Market Cap
$28.55M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
113 of 845
Rank in Industry
69 of 490

ACET Insider Trading Activity

ACET Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$1,603,934
3
60
Sells
$674,847
2
40

Related Transactions

RA CAPITAL MANAGEMENT, L.P.10 percent owner
3
$1.6M
0
$0
$1.6M
ORBIMED ADVISORS LLC10 percent owner
0
$0
2
$674,847
$-674,847

About Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.

Insider Activity of Adicet Bio, Inc.

Over the last 12 months, insiders at Adicet Bio, Inc. have bought $1.6M and sold $674,847 worth of Adicet Bio, Inc. stock.

On average, over the past 5 years, insiders at Adicet Bio, Inc. have bought $7.86M and sold $1.45M worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. (10 percent owner) — $1.6M.

The last purchase of 74,751 shares for transaction amount of $543,440 was made by RA CAPITAL MANAGEMENT, L.P. (10 percent owner) on 2026‑02‑20.

List of Insider Buy and Sell Transactions, Adicet Bio, Inc.

2026-04-08SaleORBIMED ADVISORS LLC10 percent owner
72,939
0.7583%
$6.42
$468,082
+24.96%
2026-04-07SaleORBIMED ADVISORS LLC10 percent owner
31,719
0.335%
$6.52
$206,765
+27.06%
2026-02-20PurchaseRA CAPITAL MANAGEMENT, L.P.10 percent owner
74,751
0.7946%
$7.27
$543,440
+11.55%
2026-02-19PurchaseRA CAPITAL MANAGEMENT, L.P.10 percent owner
74,268
0.7918%
$7.21
$535,472
+6.85%
2026-02-18PurchaseRA CAPITAL MANAGEMENT, L.P.10 percent owner
74,577
0.7764%
$7.04
$525,022
+12.46%
2025-10-08PurchaseORBIMED ADVISORS LLC10 percent owner
5M
6.4668%
$1.00
$5M
-44.41%
2024-06-05SaleKauffman Michaeldirector
5,900
0.0071%
$1.43
$8,437
-29.86%
2024-01-25PurchaseORBIMED ADVISORS LLC
3.13M
7.0488%
$2.40
$7.5M
-41.70%
2024-01-25PurchaseGORDON CARL L
3.13M
7.0488%
$2.40
$7.5M
-41.70%
2023-10-02PurchaseSchor ChenPresident & CEO
5,500
0.013%
$1.33
$7,340
+13.74%
2023-09-29SaleSchor ChenPresident & CEO
5,500
0.0127%
$1.36
$7,481
+9.12%
2023-09-28SaleSchor ChenPresident & CEO
5,500
0.0128%
$1.42
$7,810
+4.93%
2023-09-28PurchaseSchor ChenPresident & CEO
5,500
0.0128%
$1.42
$7,810
+4.93%
2023-06-30PurchaseDUBIN STEVEdirector
5,000
0.0115%
$2.40
$12,000
-27.78%
2023-06-27PurchaseORBIMED ADVISORS LLC
875,000
1.9987%
$2.09
$1.83M
-16.90%
2023-06-27PurchaseGORDON CARL L
875,000
1.9987%
$2.09
$1.83M
-16.90%
2023-02-15SaleHealey DonChief Technology Officer
4,533
0.0101%
$7.57
$34,327
-68.06%
2023-02-10SaleHealey DonChief Technology Officer
10,467
0.0247%
$7.98
$83,476
-68.37%
2022-11-10SaleSchor ChenPresident & CEO
39,955
0.095%
$20.30
$811,242
-72.57%
2022-11-10SaleAftab BlakeChief Scientific Officer
6,967
0.0171%
$21.00
$146,307
-72.57%
Total: 64
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
RA CAPITAL MANAGEMENT, L.P.10 percent owner
1182624
12.6329%
$3.61M30
ORBIMED ADVISORS LLC10 percent owner
0
0%
$042
<0.0001%
GORDON CARL L
7526359
80.397%
$22.96M20
<0.0001%
SILVERSTEIN JONATHAN
4830387
51.5985%
$14.73M10
PureTech Health LLC10 percent owner
2119696
22.6427%
$6.47M16
Sinclair Andrewdirector
2115385
22.5967%
$6.45M10
<0.0001%
Jakobovits Aya
356343
3.8065%
$1.09M010
Healey DonChief Technology Officer
66568
0.7111%
$203,032.4002
Galimi FrancescoSVP & Chief Medical Officer
59917
0.64%
$182,746.8501
Schor ChenPresident & CEO
43469
0.4643%
$132,580.45518
+9.34%
Aftab BlakeChief Scientific Officer
28209
0.3013%
$86,037.4506
DUBIN STEVEdirector
10900
0.1164%
$33,245.0010
<0.0001%
Kauffman Michaeldirector
5900
0.063%
$17,995.0001
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$2,542,362
111
11.81%
$36.15M
$156,891,025
80
-24.91%
$35.72M
$693,326
47
-16.24%
$33.94M
$6,204,522
45
1.91%
$33.69M
$121,435,814
28
12.32%
$30.18M
$931,435
28
16.31%
$25.5M
$2,783,837
22
-18.19%
$31.36M
$226,127
22
-27.62%
$20.62M
Adicet Bio, Inc.
(ACET)
$37,684,649
9
-19.02%
$28.55M
$2,857,792
6
-36.44%
$36.06M
$114,586
6
-12.52%
$21.16M
$8,470,804
6
-13.28%
$24.67M
$2,060,158
5
-21.35%
$20.03M
$305,717
5
-16.82%
$25.61M
$26,254,149
5
49.97%
$25.42M
$5,306,958
5
11.70%
$37.09M
$14,929
1
-8.76%
$37.31M
$35,811
1
-10.94%
$21.47M
$5,512,500
1
-7.91%
$24.4M

ACET Institutional Investors: Active Positions

Increased Positions36+59.02%4M+123.13%
Decreased Positions28-45.9%637,127-18.92%
New Positions15New3MNew
Sold Out Positions19Sold Out122,964Sold Out
Total Postitions69+13.11%7M+104.2%

ACET Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Orbimed Advisors Llc$6,310.007.15%715,44600%2025-09-30
Tang Capital Management Llc$4,533.005.14%513,97600%2025-09-30
Ra Capital Management, L.P.$4,157.004.71%471,31300%2025-09-30
Goldman Sachs Group Inc$2,068.002.35%234,476-30-0.01%2025-09-30
Vanguard Group Inc$1,804.002.05%204,53300%2025-09-30
Carlyle Group Inc.$1,625.001.84%184,29500%2025-09-30
Aquilo Capital Management, Llc$1,354.001.54%153,512-4,688-2.96%2025-03-31
Acadian Asset Management Llc$1,249.001.42%141,593+11,930+9.2%2025-09-30
Renaissance Technologies Llc$1,008.001.14%114,309+42,195+58.51%2025-09-30
Regeneron Pharmaceuticals, Inc.$534.000.61%60,51100%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.